Switching Anti-Vascular Endothelial Growth Factors in Refractory Neovascular Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in patients older than 50 years in developed countries.1 There are currently three available drugs for the treatment of neovascular AMD: off-label use of bevacizumab (Avastin; Genentech, South San Francisco, CA), on-label use of ranibizumab (Lucentis; Genentech, South San Francisco, CA), and aflibercept (Eylea; Regeneron, Tarrytown, NY). Results from randomized clinical trials (RCTs) have demonstrated the efficacy of anti-vascular endothelial growth factor (VEGF) agents in improving vision and preventing
Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - Category: Opthalmology Authors: Mohammed Ashraf, FRCOphth Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Avastin | Clinical Trials | Lucentis | Opthalmology | Ranibizumab Injection